e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Clinical issues in diffuse parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Can soluble CD-163 be related to disease activity in pulmonary sarcoidosis?
N. Milman, C. B. Svendsen, H. J. Moller (Copenhagen, Aarhus, Denmark)
Source:
Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Session:
Clinical issues in diffuse parenchymal lung disease
Session type:
Thematic Poster Session
Number:
842
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Milman, C. B. Svendsen, H. J. Moller (Copenhagen, Aarhus, Denmark). Can soluble CD-163 be related to disease activity in pulmonary sarcoidosis?. Eur Respir J 2010; 36: Suppl. 54, 842
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
IL-6 and IL-8 in stable and exacerbated IPF patients and their association to outcome
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Enhanced expression of IL-18 receptor but not soluble form of IL18R in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011
Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 377s
Year: 2003
Tumor-associated antigens in acute exacerbation of idiopathic pulmonary fibrosis: Associations with disease activity
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis
Source: Eur Respir J 2002; 19: 439-446
Year: 2002
Interleukin-18 production and pulmonary function in COPD
Source: Eur Respir J 2008; 31: 287-297
Year: 2008
COPD is associated with reduced pulmonary interstitial expression of pentraxin-3
Source: Eur Respir J 2012; 39: 830-838
Year: 2012
Endotrophin is related to disease progression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
T-bet is augmented during the pathogenesis of pulmonary sarcoidosis
Source: Annual Congress 2009 - Cell biology of lung disease
Year: 2009
IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease
Year: 2021
Expression profile of Th1/Th2 transcription factors T-bet and GATA-3 in sarcoidosis, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Year: 2010
VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis
Source: Eur Respir J 2011; 38: 1355-1360
Year: 2011
Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease
Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018
Year: 2019
Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Longitudinal serological assessment of neutrophil activity is related to disease progression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
The role anti-inflammatory cytokines in pathogenesis professional occupetional pulmonary disease
Source: Eur Respir J 2003; 22: Suppl. 45, 122s
Year: 2003
Procoagulant and antifibrynolitic activities strongly correlate with fibrosis and tissue turn-over markers in patients with active idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept